Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...

Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

For the week, Both Nasdaq and Dow declined 0.8%.Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week: Sarepta downgraded after suspending ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

GlobalData named RNAi and antisense oligonucleotides as other drivers of growth in the genomic therapy segment. The analysts are predicting RNAi sales will swell from $2.5 billion in 2024 to $18.7 ...

Stay up-to-date on Wall Street's latest analyst calls, stock downgrades, and upgrades for major companies like Sarepta, Cisco, and more.

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $109.8, a high estimate of $202.00, and a low estimate of $40.00. Highlighting a 20.62% decrease ...